Articles Related to Cisplatin
Predictive Value of ERCC1 Expression on Treatment Response to Cisplatin-Based Regimens in Small Cell Lung Cancer: A Retrospective Analysis
We aimed to determine whether the excision repair cross-complementation group 1 (ERCC1) expression predicts response to cisplatin-based chemotherapy in patients with small cell lung cancer (SCLC). This was a retrospective study, in which hospital files of 31 patients (29 males, 2 females; mean age, 62.26±7.71 years) were reviewed. All patients were treated with etoposide+cisplatin. The lung biopsy and mediastinal lymph node samples were applied anti-human monoclonal antibodies against ERCC1: immunohistochemical staining was considered positive if 25-100% of the cells showed nuclear staining, and negative if less than 25% of the cells showed negative or slight staining. Response to treatment was evaluated as regression (complete or partial response), progressive disease, or stable disease. Of the patients, 18 (58.1%) had limited-stage, and 13 (41.9%) had extensive-stage SCLC. Median follow-up duration was 15 months (range: 1-60 months). ERCC1 staining was positive in 9 of 31 patients (29.0%). In 12 patients (38.7%), tumor regression (complete or partial response) was obtained after chemotherapy. Tumor regression rate was higher in ERCC1 positive patients than those with negative ERCC1 expression (66.7% vs. 27.3%, p=0.036). In conclusion, high expression of ERCC1 was associated with higher response rate to cisplatin-based regimens in patients with SCLC.
Cisplatin-Gemcitabine Related Cardiomyopathy in Non-Small Cell Lung Cancer NSCLC Patient: A Case Study
Gemcitabine is a pyrimidine analog and cisplatin is a platinum agent, they are usually combined to form a chemotherapeutic doublet used to treat different types of oncological cancers, including non-small cell lung cancer (NSCLC). Although these agents are not known to cause such events, few cases related to possible cardiotoxicity side effects have been reported ; including angina, chronic heart failure, arrhythmias, and cardiac ischemia. A 52-year-old African male presented with Stage IV lung adenocarcinoma metastatic to the bone, pleura and lymph node, EGFR wild type. Patient has a history of hypertension, diabetes, and atrial fibrillation and on rate control medications. He was treated initially with cisplatin-gemcitabine, after which he developed cardiomyopathy.
Compliance in the Duration of Administration of Anticancer Chemotherapy: Comparative Study of Two Different Administration Modalities (PVC versus IVAD)
Objective: To evaluate the compliance of chemotherapy administration duration by comparing the peripheral venous catheter (PVC) route with the implantable venous access device (IVAD).Keywords: Chemotherapy; Gravity perfusion; Peripheral venous; Implantable venous access deviceIntroduction Methods: This was a retrospective study that analyzed 566 cycles of chemotherapy administered by PVC at the Cancer Unit of Yalgado Ouédraogo University Hospital and 258 cycles administered by IVAD at the Oncology Department of Treichville University Hospital in Abidjan. We compared the differences between the programmed duration of chemotherapy and the actual duration of administration according to the two routes of administration.
Effect of Neoadjuvant Chemoradiotherapy on Pathologic Stage and Survival in Patients with Locally Advanced Esophageal Cancer
The treatment of resectable stages of esophageal cancer often involves pre-operative concurrent chemoradiotherapy. This study aims to evaluate the effect of cisplatin/5-fluorouracil (5-FU)-based neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer.
Overuse and Misuse of Adjuvant Chemotherapy for Stages I and II Non-Small Cell Lung Cancer Chemotherapy: Empirical Findings from a Privately Insured Population
Among persons with early stage non-small cell lung cancer (NSCLC) resected for cure, appropriate use of adjuvant chemotherapy is an important additional determinant of survival. Oncology quality improvement initiatives focus on reducing overuse, underuse, and misuse.
Development of Severe Hypophosphatemia from Acquired Fanconi Syndrome during Treatment with Abiraterone
The first patient was a 77 year old man who had been on abiraterone for 12 months before his phosphorous was checked. At that point, it was 0.6 mg/dl, which is severely decreased. A full work up for hypophosphatemia showed normal parathyroid hormone and 25-hydroxyvitamin D. A urine study showed inappropriate excretion of phosphorous along with aminoaciduria and normoglycemic glucosuria.
Cancer is a highly heterogeneous disease characterised by continuous uncontrolled growth and expansion of abnormal cells. In general, in tumor cells the signalling pathways regulating cellular processes, as cell growth and division and cell to cellcommunication result strongly altered.